Skip to main content
Equibles
HALO logo

HALO · Halozyme Therapeutics, Inc.

Track HALO — free

Use HALO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$110.19 -0.57 (-0.51%) At close · Sep 4
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$12.37B
Shares
113.50M

HALO metrics

94 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$110.19
Market cap
$12.37B

Price action

19 metrics
Price change (1W)
+3.6%
Price change (30D)
+29.2%
Price change (3M)
+54.7%
Price change (6M)
+64.4%
Price change (YTD)
+64.6%
Price change (1Y)
+48.0%
Trailing year
Price change (5Y)
+162.3%
52-week high
$110.76
52-week low
$61.63
Change from 52-week high
+0.0%
Change from 52-week low
+79.7%
Annualized volatility
37.1%
Beta
0.6
RSI (14D)
74.3
Price vs SMA 50
+23.2%
Price vs SMA 200
+49.6%
Avg volume (3M)
1.97M
Relative volume
1.0
Average dollar volume
$171.49M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
113.50M

Valuation

12 metrics
P / E (TTM)
32.4
Trailing earnings · reciprocal yield 3.1%
PEG ratio
0.8
EV / revenue
8.6×
reciprocal yield 11.6%
EV / EBITDA
23.5×
reciprocal yield 4.3%
EV / EBIT
24.0×
reciprocal yield 4.2%
P / sales
7.4×
reciprocal yield 13.5%
P / book
86.2
reciprocal yield 1.2%
FCF yield
6.5%
TTM · current market cap
Buyback yield
—
P / FCF
15.3
reciprocal yield 6.5%
P / operating cash flow
15.1
reciprocal yield 6.6%
Earnings yield
3.3%

Historical valuation

8 metrics
P / E historical average (3Y)
19.7×
reciprocal yield 5.1%
P / E historical average (5Y)
20.3×
reciprocal yield 4.9%
EV / revenue historical average (3Y)
7.8×
reciprocal yield 12.8%
EV / revenue historical average (5Y)
10.7×
reciprocal yield 9.3%
EV / EBIT historical average (3Y)
17.7×
reciprocal yield 5.6%
EV / EBIT historical average (5Y)
20.2×
reciprocal yield 5.0%
EV / EBITDA historical average (3Y)
17.3×
reciprocal yield 5.8%
EV / EBITDA historical average (5Y)
19.7×
reciprocal yield 5.1%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
83.6%
Operating margin
35.9%
Trailing 12 months
Net margin
24.9%
Gross profit (TTM)
$12.62M
Operating profit (TTM)
$597.20M
Net income (TTM)
$413.60M
Trailing 12 months
Diluted EPS (TTM)
$3.42
FCF margin
48.5%
Effective tax rate
29.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$0.09
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.20

Growth

11 metrics
Revenue growth YoY
+47.7%
Year over year
Net income growth YoY
+39.2%
Revenue (TTM)
$1.66B
Trailing 12 months
EPS growth YoY
+42.9%
Shares change YoY
-2.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+28.4%
Revenue CAGR (5Y)
+39.2%
EPS CAGR (3Y)
+21.1%
EPS CAGR (5Y)
+23.0%
FCF CAGR (3Y)
+39.9%
FCF CAGR (5Y)
+64.8%

Quality

14 metrics
Return on equity
288.1%
Return on assets
16.0%
Debt / equity
15.0
Current ratio
2.7
EBITDA (TTM)
$611.92M
Free cash flow (TTM)
$806.22M
Quick ratio
2.3
Interest coverage
29.4
Net debt / EBITDA
3.2
Return on invested capital
19.9%
Trailing 12 months
Net cash
−$1.98B
Latest balance sheet
Cash & equivalents
$163.14M
Total assets
$2.58B
Total debt
$2.15B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$818.60M
Capital expenditures (TTM)
$12.37M
R&D (TTM)
$102.37M
SG&A (TTM)
$238.00M
Stock compensation (TTM)
$63.07M
R&D / revenue
6.2%
Stock compensation / revenue
3.8%

Ownership (13F)

3 metrics
13F filers
669
13F filer change QoQ
+32
Institutional ownership
109.2%

Short interest

3 metrics
Short interest
12.9%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$7.27M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1159036 CUSIP 40637H109 13F (30d) 407 filings 386 filers Visit website Investor relations